Investor Relations

IDEAYA is a precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Our approach integrates capabilities in identifying and validating translational biomarkers with small molecule drug discovery to select patient populations most likely to benefit from our targeted therapies.

Investor Presentation

Download PDF

Recent News

Investor Alerts

Jul 11, 2024

IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

IDEAYA Biosciences, Inc. (Nasdaq: IDYA) today announced the closing of its underwritten public offering of 8,355,714 shares of its common stock at a public offering price of $35.00 per share,...

Jul 9, 2024

IDEAYA Announces Pricing of Public Offering

IDEAYA Biosciences, Inc. (Nasdaq: IDYA) today announced the pricing of an underwritten public offering of common stock and pre-funded warrants. IDEAYA is selling 7,228,572 shares of common stock...

Jul 9, 2024

IDEAYA Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

IDEAYA Biosciences, Inc. (Nasdaq:IDYA) today announced that it intends to offer and sell up to $200.0 million of shares of its common stock and, in lieu of common stock, to offer and sell to...

All Releases

Events

IDEAYA Biosciences Phase 2 Clinical Data Update for IDE397 in MTAP-Deletion Urothelial and NSCLC

Monday, July 8, 2024

8:00am EDT

A replay is available through the following link:
https://lifescievents.com/event/ideaya-2/

Goldman Sachs 45th Annual Global Healthcare Conference

Monday, June 10, 2024

8:00am - 9:00am EDT

Fireside chat with Yujiro S. Hata, Chief Executive Officer, hosted by Corinne (Jenkins) Johnson, Vice President, Equity Research, Biotechnology

All Events

Investor Resources